Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Molecular Urine Test Validated for Schistosomiasis

By LabMedica International staff writers
Posted on 16 Jan 2012
Urogenital schistosomiasis in chronically infected adults can be diagnosed by the detection of parasite specific DNA fragments. More...


The sensitivity and specificity of three tests have been evaluated for the viable infection of Schistosoma haematobium in the urogenital tract, which included a polymerase chain reaction hematuria, and the presence of parasite eggs.

A team of collaborating scientists under the auspices of those at Johns Hopkins University (Baltimore, MD, USA) collected over 400 urine samples from adult volunteers in an endemic area in Western Nigeria. These were assessed for hematuria then filtered in the field, the filter papers dried and later examined for eggs and DNA. The results were stratified according to sex and age and subjected to Latent Class analysis.

The DNA was precipitated and concentrated using the Qiagen QIAmp (Qiagen; Germantown, MD, USA) mini- kit. The extracted DNA was used for PCR amplification. The primers were designed to amplify the 121 bp tandem repeat restriction endonuclease from Deinococcus radiophilus (Dra-1) sequence of S. haematobium. Each urine sample was tested with a Hemastix (Bayer; Elkhart, IN, USA) test strip to detect hematuria.

The PCR test indicating the presence of Dra1 DNA fragments in males was 100% for both sensitivity and specificity. This exceeded hematuria with a sensitivity and specificity of 87.6% and 34.7%, respectively, while the detection of eggs, the sensitivity was 70.1% and specificity was 100%. There were similar results for the females except the specificity of the hematuria was 77.0%.

To test the effect of parasite clearance on the persistence of Dra1 fragment, a group of 55 persons who were positive either for presence of parasites eggs and/or DNA in the urine, were followed up two weeks after treatment with praziquantel. Of these 26 (47.3%) were positive for parasite eggs and 42 (76.4%) were positive for DNA. None of these people were positive for eggs or parasite specific DNA in the follow up.

The authors concluded that the molecular test is extremely promising for the diagnosis of urogenital schistosomiasis and should also be useful in field studies as it will be able to reveal infections in people frequently presumed to be uninfected. The PCR test indicated the presence of schistosomes in 10.7% of adults who did not pass eggs in urine specimens. The study was published online on January 3, 2012, in the journal Public Library of Science Neglected tropical Diseases (PLoSNTD).

Related Links:

Johns Hopkins University
Qiagen
Bayer



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Sample Transportation System
Tempus1800 Necto
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.